Any focus on the cost of treatment is incredibly misguided when it comes to personalised medicines because it belies the reality of what they will provide - governments will be paying for less failure and the potential for cures will mean patients will be treated with fewer therapies.
What happens when the government is paying for less failure?
August 7, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AbbVie records 13-year streak as 'A Great Place to Work'
July 29, 2026 - - Latest News -
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
July 29, 2026 - - Latest News -
AFT Pharmaceuticals sees significant opportunity in a diverse R&D pipeline
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News

